Tag: EU
Lupin receives European Commission approval for Biosimilar Ranibizumab
Lupin’s biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany)
Beyond Trade: How the EU–India FTA reshapes life-sciences industry
The deal represents nearly 25% of global GDP and one-third of global trade, making it one of the most consequential trade agreements of this era
Lupin receives positive CHMP opinion for Biosimilar Ranibizumab
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A)
Biocon Biologics secures market entry date for Denosumab biosimilars in...
The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025
Godavari Biorefineries’ anti-cancer patent secures key European validations
Anti-cancer patent now validated in Spain, the UK, and as a unitary patent covering multiple EU member states
Loopworm secures prestigious EU TRACES certification for silkworm pupae-derived products, opens...
This milestone positions Loopworm, which operates a GMP+, ISO 22000, and HACCP-certified facility with a 6,000 metric tonnes per annum capacity, as a key player in the EU market for sustainable protein sources
Auxein strengthens its leadership in global orthopaedic solutions with EU-MDR certification
Asia’s first orthopaedic implant manufacturing organization to reach this milestone for its Trauma Orthopaedic Solutions for Trauma Plating, Screws, and Nailing Systems
Exclude medical devices from the list of India-EU Free Trade Agreement...
India already dependent on imports of medical devices to the tune of 70% presently
OPPI welcomes Indian govt’s move to waive off local clinical trials...
This will be applicable to a few select drugs already approved in well-regulated markets like the USA, UK, Japan, Australia, Canada, and the EU
Lupin completes Phase 3 trials for Lucentis Biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU